Mode
Text Size
Log in / Sign up
N/A N=100 Randomized Single-blind Supportive Care

Opioid-free Analgesia for the Management of Acute Post-operative Pain Following Caesarean Section

Acute Post-operative Pain Following Caesarean Section

Enrolled (actual)
100
Serious AEs
1.0%
Results posted
Jul 2023
Primary outcome: Primary: Post-operative Pain Scores Following Caesarean Section at 4 Hours Post-operative — 2.98; 3.16 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Magnesium sulphate (Drug); Pentazocine (Drug)
Age
Pediatric, Adult, Older Adult
Sex
Female
Sponsor
Olakunle Ifeoluwa Makinde
Primary completion
Mar 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Post-operative Pain Scores Following Caesarean Section at 4 Hours Post-operative
2.98; 3.16
PRIMARY
Post-operative Pain Scores Following Caesarean Section at 8 Hours Post-operative
2.58; 2.68
PRIMARY
Post-operative Pain Scores Following Caesarean Section at 24 Hours Post-operative
2.06; 2.37
PRIMARY
Post-operative Pentazocine Use
46; 50; 4; 0
PRIMARY
Pentazocine Use as Rescue Analgesia
46; 0; 4; 50
PRIMARY
Frequency and Nature of Pentazocine Use
0; 0; 0; 50; 0; 0
PRIMARY
Mean Dose of Pentazocine Used
52.83; 164.40
SECONDARY
Number of Participants With Peri-operative Adverse Events
0; 2; 50; 48; 14; 5
SECONDARY
Number of Participants With Post-operative Adverse Events
0; 0; 0; 4; 46; 50
SECONDARY
Apgar Scores of the Neonates
0; 0; 2; 6; 48; 44

Summary

Background: Multimodal analgesia; a combination of opioid and non-opioid analgesics, for management of acute post-operative pain significantly reduces the incidence of adverse effects associated with liberal post-operative opioid use including sedation, respiratory depression, constipation, ileus, urinary retention, delayed recovery, addiction etc. However, opioid addiction remains a worsening public health problem and have followed administration of opioid analgesics for post-operative pain and subsequent chronic use in many addicts; especially the opioid naive. Caesarean section is a commonly performed surgery and is a common source of first exposure to opioids in women. Trend in post-operative analgesia is moving towards opioid-free (multimodal) analgesia; a combination of non-opioid and adjuvant analgesics. Magnesium sulphate is an adjuvant analgesic. When administered peri-operatively, it has been reported to prolong the duration of spinal anaesthesia, decrease post-operative pain and opioid use without adverse effect. Aim: To determine the effectiveness and safety of a combination of peri-operative intravenous magnesium sulphate, intravenous paracetamol, and post-operative rectal diclofenac as opioid-free, multimodal analgesia for management of acute post-operative pain after a caesarean section. Null Hypothesis: Combination of intravenous magnesium sulphate, intravenous paracetamol, and rectal diclofenac as analgesia regimen for acute post-operative pain after a caesarean section is not as effective and safe as a routine opioid-based multimodal analgesia regimen used in the study setting. Alternate Hypothesis: Combination of intravenous magnesium sulphate, intravenous paracetamol, and rectal diclofenac as analgesia regimen for acute post-operative pain after a caesarean section is as effective and safe as a routine opioid-based multimodal analgesia regimen used in the study setting. Materials and Methods: A randomized clinical trial, comparing a combination of peri-operative intravenous magnesium sulphate, intravenous paracetamol, and post-operative rectal diclofenac with an opioid-based multimodal regimen as control. Eligible patients will be consecutively selected from among women booked for caesarean section at the Federal Medical Centre, Yenagoa. Control group will receive a combination of post-operative intramuscular pentazocine, intravenous paracetamol and rectal diclofenac. Pain intensity will be determined in both groups and compared. Need for rescue opioid analgesic will be determined in both groups and compared. Incidence of any adverse event in both groups will be determined.

Eligibility Criteria

Inclusion Criteria

  • Pregnant women booked for elective, scheduled and urgent caesarean section at the Federal Medical Centre, Yenagoa, Bayelsa State during the study period,
  • Pregnant women who give consent to participate in the study.

Exclusion Criteria

  • Pregnant women with active peptic ulcer disease, active liver disease, hepatic failure, and renal failure,
  • Pregnant women with previous history of ischaemic heart disease/myocardial infarction, heart failure, venous thrombosis and stroke,
  • Hypersensitivity to pentazocine, paracetamol, diclofenac or magnesium sulphate,
  • Pregnant women with history of non-medical use (abuse) of opioids,
  • Pregnant women on magnesium sulphate or have a clinical indication to receive magnesium sulphate,
  • Pregnant women booked for emergency caesarean section (because the urgency may not allow time for adequate patient counseling before recruitment)
  • Pregnant women booked for caesarean section under general anaesthesia or epidural anaesthesia,
  • Pregnant women who can neither communicate in english nor colloquial english.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04539249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search